Mesothelioma: all 475 studies

Page 3 of 5. Open to participants first (75), then studies with results posted, then the rest; newest registration first within each.

• A Study of Pembrolizumab and Cryoablation in People With MesotheliomaCompletedNCT05071014Phase 1
• Real World Study of MPM in ChinaStatus unknownNCT05042557
• Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to DrugsWithdrawnNCT04985357
• UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLCStatus unknownNCT04940637Phase 2
• Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesActive, not recruitingNCT04913337Phase 1/2
• A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid TumorsActive, not recruitingNCT04857372Phase 1
• Dielectric Properties of Matched Tissue Samples From Thoracic Malignancies and Corresponding Normal TissuesStatus unknownNCT04804410Not applicable
• Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing TumorsActive, not recruitingNCT04802876Phase 2
• Evaluation of the Clinical/Biological Characteristics, Efficacy and Safety of Patients With Malignant Pleural Mesothelioma, Treated by ImmunotherapyCompletedNCT04775446
• Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced CancerCompletedNCT04670445Not applicable
• αPD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid TumorsStatus unknownNCT04489862Early Phase 1
• Intravenous Magnesium in Patients Receiving CisplatinCompletedNCT04481672Phase 1
• SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph IICompletedNCT04480372Phase 2
• Efficacy of a Maintenance Treatment With TALAzoparib Following First Line Platinum-based Chemotherapy in Malignant MESOtheliomaStatus unknownNCT04462809Phase 2
• The Transitions Project: Supporting Adults During the Shift From Cancer Treatment to SurveillanceActive, not recruitingNCT04450043Not applicable
• Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072SCompletedNCT04430842Phase 1
• Cryoablation for the Promotion of Local Tumor Infiltration in Patients With MesotheliomaWithdrawnNCT04429204Not applicable
• 177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive TumoursCompletedNCT04375267Phase 1
• A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic CancersActive, not recruitingNCT04328844Phase 1
• First-in-human Study of S-588210 (S-488210+S-488211)CompletedNCT04316689Phase 1
• Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid TumorsTerminatedNCT04301011Phase 1
• Nivolumab and Ipilimumab +/- UV1 Vaccination as Second Line Treatment in Patients With Malignant MesotheliomaActive, not recruitingNCT04300244Phase 2
• HMPL-453 in Advanced Malignant MesotheliomaStatus unknownNCT04290325Phase 2
• Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma PatientsActive, not recruitingNCT04287829Phase 2
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid TumorsTerminatedNCT04272034Phase 1
• Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid TumorsCompletedNCT04242199Phase 1
• A Pilot Study to Explore the Role of Gut Flora in Metastatic MesotheliomaWithdrawnNCT04214015
• Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric PatientsTerminatedNCT04213794Early Phase 1
• Pembrolizumab + Defactinib In Pleural MesotheliomaWithdrawnNCT04201145Phase 1
• Nivolumab with Chemotherapy in Pleural Mesothelioma After SurgeryCompletedNCT04177953Phase 2
• Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant MesotheliomaTerminatedNCT04173338Phase 1
• Diadem to Investigate the Activity and Safety of DurvalumabCompletedNCT04115111Phase 2
• Phase I Trial HIPEC With Nal-irinotecanCompletedNCT04088786Phase 1
• A Single Dose FMT Infusion as an Adjunct to Keytruda for Metastatic MesotheliomaCompletedNCT04056026Early Phase 1
• A Study of SGN-CD228A in Advanced Solid TumorsTerminatedNCT04042480Phase 1
• Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in MesotheliomaCompletedNCT04040231Phase 1
• A Non-Interventional Pilot Study to Explore the Role of Gut Flora in DiseaseSuspendedNCT04031469
• A Feasibility Study Evaluating Surgery for Mesothelioma After Radiation Therapy Using Extensive Pleural ResectionActive, not recruitingNCT04028570Not applicable
• The Registry of Oncology Outcomes Associated with Testing and TreatmentCompletedNCT04028479
• MTG201 Plus Nivolumab in Patients With Relapsed Pleural MesotheliomaStatus unknownNCT04013334Phase 2
• Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.Active, not recruitingNCT03983954Phase 1
• Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid CancersActive, not recruitingNCT03935893Phase 2
• INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)WithdrawnNCT03920839Phase 1
• Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural MesotheliomaActive, not recruitingNCT03918252Phase 2
• Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing CancerActive, not recruitingNCT03907852Phase 1/2
• Magnetic Resonance Imaging for Detection of Peritoneal MesotheliomaCompletedNCT03867578Not applicable
• Study of Recombinant Human Anti-PD-1 Monoclonal Antibody in Patients With Advanced TumoursStatus unknownNCT03852823Phase 1
• Feasibility of the LUM Imaging System for Peritoneal Surface MalignanciesCompletedNCT03834272Phase 1/2
• A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural MesotheliomaWithdrawnNCT03786419Phase 2
• Dose Individualization of Pemetrexed - IMPROVE-ICompletedNCT03656549Phase 4
• Dose Individualization of Pemetrexed - IMPROVE-IIICompletedNCT03655834Phase 4
• Dose Individualization of Pemetrexed - IMPROVE-IITerminatedNCT03655821Phase 4
• A Safety and Tolerability Study of INCAGN02390 in Select Advanced MalignanciesCompletedNCT03652077Phase 1
• Autologous CAR-T/TCR-T Cell Immunotherapy for MalignanciesStatus unknownNCT03638206Phase 1/2
• DENdritic Cell Immunotherapy for MesotheliomaCompletedNCT03610360Phase 2/3
• Intraperitoneal MCY-M11 (Mesothelin-targeting CAR) for Treatment of Advanced Ovarian Cancer and Peritoneal MesotheliomaTerminatedNCT03608618Phase 1
• A Double Blind, Placebo Controlled, Randomized Phase II Study Evaluating Gemcitabine With or Without Ramucirumab , for II Line Treatment MPMCompletedNCT03560973Phase 2
• IP3R Modulation by Cancer Genes in MesotheliomaStatus unknownNCT03558932
• Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients with PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior TherapiesActive, not recruitingNCT03546426Phase 1
• A Safety and Tolerability Study of INCAGN02385 in Select Advanced MalignanciesCompletedNCT03538028Phase 1
• Association Between Proton Pump Inhibitors and Hematologic Toxicity of PemetrexedCompletedNCT03537833
• A Study of XmAb®20717 in Subjects With Selected Advanced Solid TumorsCompletedNCT03517488Phase 1
• First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express MesothelinCompletedNCT03507452Phase 1
• MesoTRAP: A Study Comparing Video-assisted Thoracoscopic Partial Pleurectomy/Decortication With Indwelling Pleural Catheter in Patients With Trapped Lung Due to Malignant Pleural Mesothelioma.CompletedNCT03412357Not applicable
• Combination of Immunotherapy and Hyperthermia in Advanced Malignant MesotheliomaTerminatedNCT03393858Phase 1/2
• Confocal Laser Endomicroscopy in Pleural MalignanciesStatus unknownNCT03290183
• Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma.CompletedNCT03213301Phase 2
• Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced CancersActive, not recruitingNCT03212404Phase 1
• International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)Status unknownNCT03210298
• Clinical Study of YS110 in Patients With Malignant Pleural MesotheliomaCompletedNCT03177668Phase 1/2
• Malignant Mesothelioma - Can we Improve Quality of LifeCompletedNCT03068117Not applicable
• CheckpOiNt Blockade For Inhibition of Relapsed MesotheliomaCompletedNCT03063450Phase 3
• Ipilimumab and Nivolumab in the Treatment of Malignant Pleural MesotheliomaCompletedNCT03048474Phase 2
• Thrombin Generation and Platelet Activation in CRS/HIPECCompletedNCT03034850
• Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid TumorsCompletedNCT03023319Phase 1
• Chest Wall Motion Analysis in DiseaseCompletedNCT02958683
• Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical TrialsCompletedNCT02948413
• A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural MesotheliomaStatus unknownNCT02879669Phase 1/2
• A Study to Assess Long-term Safety of Tazemetostat in Adult Participants of All Ages With Any Disease Treated With Tazemetostat in a Previous Clinical StudyCompletedNCT02875548Phase 1/2
• Study of Cytoreductive Surgery and Hyperthermic Intraoperative Chemotherapy With Pemetrexed and Cisplatin for MPMTerminatedNCT02838745Phase 1
• Genomic Analysis of Peritoneal Mesothelioma by CGH ArraysCompletedNCT02834234
• French National Registry of Rare Peritoneal Surface MalignanciesStatus unknownNCT02834169
• Effect of Expression of CD74 and VEGF on Outcome of Treatment in Patients With Malignant Pleural MesotheliomaStatus unknownNCT02761863
• Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)Status unknownNCT02758587Phase 1/2
• uPAR-PET for Prognostication in Patients With Non-small Cell Lung Cancer, Malignant Pleural Mesothelioma and Large Cell Neuroendocrine Carcinoma of the LungStatus unknownNCT02755675Phase 2
• Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung DisordersTerminatedNCT02748798Early Phase 1
• Nivolumab Monotherapy or Nivolumab Plus Ipilimumab, for Unresectable Malignant Pleural Mesothelioma (MPM) PatientsCompletedNCT02716272Phase 2
• A Pilot Window-Of-Opportunity Study of the Anti-PD-1 Antibody Pembrolizumab in Patients With Resectable Malignant Pleural MesotheliomaTerminatedNCT02707666Phase 1
• Cardiac MRI Biomarker Testing (GCC 1618)TerminatedNCT02688166
• Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural MesotheliomaCompletedNCT02662504Phase 2
• A Phase Ib Trial of a Maintenance Multipeptide Vaccine (S-588210) in Patients With Unresectable Malignant Pleural Mesothelioma Without Progression After First-Line ChemotherapyWithdrawnNCT02661659Phase 1
• A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor PatientsWithdrawnNCT02661100Phase 1/2
• Autologous Dendritic Cell Vaccination in MesotheliomaCompletedNCT02649829Phase 1/2
• Staging Procedures to Diagnose Malignant Pleural MesotheliomaTerminatedNCT02648763
• Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural MesotheliomaWithdrawnNCT02639767Phase 1
• Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid TumorsCompletedNCT02639091Phase 1
• A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549Status unknownNCT02637531Phase 1
• Safety Study of MGD009 in B7-H3-expressing TumorsTerminatedNCT02628535Phase 1
• Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)Active, not recruitingNCT02628067Phase 2
• Chemotherapy Followed by Surgery and Neoadjuvant Hemothoracic Intensity Modified Radiation Therapy (IMRT) for Patients With Malignant Pleural MesotheliomaTerminatedNCT02613312

← Mesothelioma overview